In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS they review the clinical trial and real-world evidence on the efficacy and safety of currently available therapies for patients with lower-risk myelodysplastic syndrome (LR-MDS)-associated anemia. Their thought-provoking discussion will give an overview of the pertinent publications while highlighting the clinical implications of this data, in practice.

Visit https://suitehome.atpointofcare.com/library/2729.02/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS explore dose escalation strategies for the erythroid maturation agent (EMA), luspatercept, in patients with lower-risk myelodysplastic syndrome (LR-MDS). Their engaging discussion will give an overview of the pertinent clinical trial efficacy and safety data and recent changes to the prescribing information, as well as delving into how they both apply this information in their clinical practices.

Visit https://suitehome.atpointofcare.com/library/2729.01/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn

In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs).

Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.